Haemonetics Co. (NYSE:HAE) SVP Jacqueline Scanlan sold 1,531 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $127.44, for a total transaction of $195,110.64. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Jacqueline Scanlan also recently made the following trade(s):
- On Monday, June 17th, Jacqueline Scanlan sold 3,646 shares of Haemonetics stock. The shares were sold at an average price of $112.49, for a total value of $410,138.54.
NYSE:HAE traded up $2.55 during midday trading on Wednesday, reaching $123.28. The stock had a trading volume of 436,965 shares, compared to its average volume of 452,806. The stock has a market capitalization of $6.15 billion, a P/E ratio of 51.58, a PEG ratio of 2.90 and a beta of 0.81. Haemonetics Co. has a 1-year low of $80.24 and a 1-year high of $140.36. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.10 and a quick ratio of 1.34. The firm’s fifty day simple moving average is $129.67 and its 200-day simple moving average is $106.59.
Several institutional investors have recently bought and sold shares of HAE. Alpha Windward LLC bought a new stake in Haemonetics during the 2nd quarter valued at approximately $29,000. Financial Gravity Wealth Inc. acquired a new stake in Haemonetics in the 2nd quarter valued at approximately $40,000. Harvest Fund Management Co. Ltd acquired a new stake in Haemonetics in the 2nd quarter valued at approximately $42,000. Steward Partners Investment Advisory LLC bought a new position in Haemonetics in the 2nd quarter worth approximately $90,000. Finally, CSat Investment Advisory L.P. bought a new position in Haemonetics in the 2nd quarter worth approximately $143,000. Institutional investors and hedge funds own 99.57% of the company’s stock.
A number of brokerages have weighed in on HAE. Morgan Stanley boosted their price target on Haemonetics from $128.00 to $148.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Raymond James increased their price objective on Haemonetics from $110.00 to $150.00 and gave the company an “outperform” rating in a report on Wednesday, August 7th. Barrington Research reissued an “outperform” rating and issued a $139.00 price objective (up from $116.00) on shares of Haemonetics in a research note on Wednesday, August 7th. Jefferies Financial Group boosted their target price on Haemonetics from $125.00 to $140.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Finally, JMP Securities upped their target price on Haemonetics to $145.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Haemonetics has a consensus rating of “Buy” and an average price target of $140.67.
Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.
Featured Article: The mechanics of the bid-ask spread in trading
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.